Visceral Leishmaniasis Recent Advances in Diagnostics and Treatment Regimens
Visceral Leishmaniasis Recent Advances in Diagnostics and Treatment Regimens
复制标题
DOI：
10.1016/j.idc.2018.10.005
复制
发表时间：
2019-03-01
影响因子：
4.4
通讯作者：
Diro, Ermias
中科院分区：
文献类型：
--
作者：
van Griensven, Johan;Diro, Ermias
内脏利什曼病的诊断进展包括rK39和rK28快速诊断试验的发展。直接凝集试验以及常规和实时聚合酶链反应的应用也越来越多，在外周血中也有很好的表现。内脏利什曼病的治疗选择取决于感染发生的地理区域。两性霉素B脂质体在世界大多数流行区域通常是安全有效的；尽管锑的毒性很高，但它在东非仍然是最有效的。联合治疗的探索越来越多。免疫抑制患者需要适应的诊断和治疗策略。
Diagnostic advances in visceral leishmaniasis include the development of the rK39 and rK28 rapid diagnostic test. The direct agglutination test is also increasingly used, as well as conventional and real-time polymerase chain reaction, which also performs well on peripheral blood. The choice of treatment for visceral leishmaniasis depends on the geographic region where the infection is acquired. Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world; antimonials still remain to be the most effective in eastern Africa despite its high toxicity. Combination therapy is increasingly explored. Immunosuppressed patients require adapted diagnostic and therapeutic strategies.